Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

ABSTRACT: Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

PROVIDER: PRJNA750792 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15299849.fastq.gz	Fastqsanger.gz
	SRR15299850.fastq.gz	Fastqsanger.gz
	SRR15299851.fastq.gz	Fastqsanger.gz
	SRR15299852.fastq.gz	Fastqsanger.gz
	SRR15299853.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 258

Similar Datasets

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

| PRJNA750781 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

| PRJNA769684 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

| PRJNA750798 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-12-21 | GSE181152 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

Project description:This study reveals supeior efficiacy of triple combination treatment (TCT) based on anti-PD-(L)1 and anti-4-1BB/OX40 and describes immunological mechanisms underlying synergism between the treatment components

2021-12-21 | GSE185566 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

2021-12-21 | GSE181150 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

2021-12-21 | GSE181142 | GEO

Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

Project description:Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

| PRJNA1001913 | ENA

Single-cell RNA-seq of tumor-infiltrating lymphocytes in metastatic uveal melanoma

Project description:Metastatic uveal melanoma generally responds poorly to immunotherapy. The aim here was to sequence tumor-infiltrating lymphocytes from uveal melanoma metastases to study their phenotypes and T-cell receptor (TCR) clonotypes. We performed paired single-cell transcriptome and TCR sequencing using the 10x Genomics platform of IL2-expanded tumor-infiltrating lymphocytes from 7 liver and 1 subcutaneous metastasis.

2020-03-16 | E-MTAB-8846 | biostudies-arrayexpress

Single-cell profiling guided combinatorial immunotherapy for breast cancer resistance to Her2/neu and CDK4/6 targeted therapy

Project description:Trastuzumab (Herceptin™), a humanized monoclonal antibody targeting the extracellular domain of human epidermal growth factor receptor-2 (HER2), is one of the most successful examples of targeted therapies for HER2-positive breast cancer. However, drug resistance remains daunting challenges. New combinatorial regimen of CDK4/6 inhibitors plus trastuzumab is currently under active clinical investigations. In this study, we seek to prospectively model the in vivo response to CDK4/6 inhibitor Palbociclib (Pal) plus trastuzumab (Ab) using transgenic Her2/Neu mouse model in parallel with the current clinical trial scenario. We performed single cell RNA-seqencing (Drop-seq) to profile and compare tumor cells and infiltrated immune cells derived from control, Ab+Pal sensitive/residual (APS) and resistant/progressive (APR) tumors. We revealed that although Ab+Pal treatment enhanced antigen processing, presentation and interferon signaling on tumor cells, a distinct immunosuppressive immature myeloid cells (IMCs) infiltrated in the resistant tumor microenvironment to promote resistant phenotype. Based on single cell gene set enrichment analysis (profiling) guided drug screening, we identified and evaluated a combinatorial immunotherapy regimen. We found that combinatorial immunotherapy with receptor tyrosine kinase inhibitor Cabozantinib and immune checkpoint blockades overcome Ab+Pal resistance by inhibiting IMCs and enhancing anti-tumor immunity. Moreover, our rationally designed sequential combinatorial regimens enabled durable response and sustained controlling of the emergence of acquired resistance, thus significantly improved outcomes of rapidly evolving Her2/Neu positive breast cancers. Our results implicate that single-cell RNA sequencing profiling guided combinatorial immunotherapy as a strategy to mitigate the emergence of resistance and to achieve long-term therapeutic benefit merits clinical translation.

2019-06-19 | GSE122336 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data